Numerous studies have firmly established the regulatory role of inflammatory cytokines in cancer.[2, 4-8, 11, 48] We recently reported the reduction of prostate size and suppression of inflammatory cytokines by GHRH antagonists in an experimental BPH rodent model.[42] This study supplements our previous work by demonstrating similar effects on in vivo cytokine gene expression in HCC1806 and MX-1 human TNBC. Here, MX1 is linked to benign prostatic hyperplasia.